Muscular Atrophy, Spinal: Clinical Trials

71 trials for Muscular Atrophy, Spinal, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

40 completed, 10 recruiting, 10 terminated, 6 unknown. 71 Phase 2, 25 Phase 1, 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 271Completed 40, Recruiting 10, Terminated 10, Unknown 6, Active not recruiting 5
Phase 125Completed 10, Recruiting 6, Unknown 4, Terminated 3, Active not recruiting 2
Phase 34Completed 3, Active not recruiting 1

Follow Muscular Atrophy, Spinal: new trials by email Literature Review of Muscular Atrophy, Spinal trials Research Report on Muscular Atrophy, Spinal

Trials (filtered) newest first · largest first

All 71 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I
SKG0201 Injection - Spinal Muscular Atrophy 1
Phase 1 / Phase 2RecruitingLanyue Biotech (Hangzhou) Co., Ltd.112026-07-152026-10-14
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
AZD9750, AZD5305 - Prostate Cancer
Phase 1 / Phase 2Active not recruitingAstraZeneca62026-01-272026-10-02
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Tulmimetostat, Darolutamide, Abiraterone - Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Phase 1 / Phase 2RecruitingNovartis Pharmaceuticals1812026-01-132026-11-13
Study of Safety, Tolerability and Efficacy of GB221 in Infants With Spinal Muscular Atrophy Type 1
GB221 - Spinal Muscular Atrophy Type I
Phase 1 / Phase 2RecruitingGemma Biotherapeutics222026-01-062026-06-29
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
ARGX-119 IV, Placebo IV - Spinal Muscular Atrophy (SMA)
Phase 2Recruitingargenx602025-12-192026-11-18
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
Apitegromab, Nusinersen, Risdiplam - Spinal Muscular Atrophy, SMA
Phase 2RecruitingScholar Rock, Inc.522025-09-152026-10-02
Clinical Trial of Mexiletine Hydrochloride for Spinal and Bulbar Muscular Atrophy
Mexiletine hydrochloride, Placebo - Spinal and Bulbar Muscular Atrophy
Phase 2 / Phase 3Active not recruitingMasahisa Katsuno682025-02-282026-11-17
An Open Label Study of Gene Therapy Product (Vesemnogene Lantuparvovec) in Spinal Muscular Atrophy
vesemnogene lantuparvovec - Spinal Muscular Atrophy
Phase 1 / Phase 2Active not recruitingLantu Biopharma202024-10-202026-06-15
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients
GC101 - Spinal Muscular Atrophy Type 3
Phase 1 / Phase 2RecruitingGeneCradle Inc212024-05-102026-11-17
A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy
Risdiplam - Muscular Atrophy, Spinal
Phase 2CompletedHoffmann-La Roche112024-04-262026-06-22
A Placebo-controlled Study of Clenbuterol in Spinal and Bulbar Muscular Atrophy
Clenbuterol, Placebo - Spinal and Bulbar Muscular Atrophy
Phase 2RecruitingGianni Soraru902024-04-132024-04-15
Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer
Abemaciclib, Bicalutamide - Triple Negative Breast Neoplasms
Phase 2RecruitingUniversitaire Ziekenhuizen KU Leuven532024-04-082026-04-01
A Study of NIDO-361 in Patients With SBMA
NIDO-361, Placebo - Spinal and Bulbar Muscular Atrophy, Kennedy's Disease
Phase 2CompletedNido Biosciences, Inc.542024-03-012026-03-03
Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy
NMD670, Placebo - Spinal Muscular Atrophy
Phase 2CompletedNMD Pharma A/S522023-09-212026-06-03
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 2 Patients
GC101 - SMA II
Phase 1 / Phase 2CompletedGeneCradle Inc292023-08-012026-11-17
Toxicity and Efficacy Evaluation of Topical Minoxidil in Acne Vulgaris
topical minoxidil in Acne Vulgaris - Acne Vulgaris
Phase 1 / Phase 2UnknownChang Gung Memorial Hospital262023-07-112023-11-03
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients
AJ201, Placebo - Spinal and Bulbar Muscular Atrophy, Kennedy's Disease
Phase 1 / Phase 2CompletedAnnJi Pharmaceutical Co., Ltd.252023-02-282024-08-15
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients
GC101 - Spinal Muscular Atrophy
Phase 1 / Phase 2RecruitingGeneCradle Inc182023-02-252026-11-17
Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1
EXG001-307 injection - Spinal Muscular Atrophy Type I
Phase 1 / Phase 2UnknownGuangzhou Jiayin Biotech Ltd122023-02-162024-09-19
Study of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying the SMN Gene After a Single Intravenous Administration of Escalating Doses in Children With Spinal Muscular Atrophy (BLUEBELL)
ANB-004, dose 1, ANB-004, dose 2, ANB-004, dose 3 - Spinal Muscular Atrophy (SMA)
Phase 1 / Phase 2RecruitingBiocad402023-02-022024-02-22

Showing 20 of 71. Sign in to see all of them.

Narrower conditions

Bulbo-Spinal Atrophy, X-Linked (23)  ·  Spinal Muscular Atrophies of Childhood (16)  ·  Motor Neuron Disease (7)  ·  Prostatic Neoplasms (7)  ·  Amyotrophic Lateral Sclerosis (5)  ·  Breast Neoplasms (3)  ·  Muscle Cramp (2)  ·  Neoplasm Metastasis (2)  ·  Neuromuscular Diseases (2)  ·  Neuromuscular Manifestations (2)  ·  Salivary Gland Neoplasms (2)  ·  Triple Negative Breast Neoplasms (2)  ·  Acne Vulgaris (1)  ·  Adenocarcinoma (1)

Broader conditions

Central Nervous System Diseases (71)  ·  Spinal Cord Diseases (71)  ·  Nervous System Diseases (70)  ·  Neurodegenerative Diseases (70)  ·  Neuromuscular Diseases (69)  ·  Motor Neuron Disease (64)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (40)  ·  Genetic Diseases, Inborn (39)  ·  Heredodegenerative Disorders, Nervous System (39)  ·  Genetic Diseases, X-Linked (23)  ·  Neoplasms (13)  ·  Neoplasms by Site (13)  ·  Pathological Conditions, Signs and Symptoms (8)  ·  Genital Diseases (7)

Interventions

Risdiplam (7)  ·  bicalutamide (5)  ·  nusinersen (5)  ·  4-phenylbutyric acid (3)  ·  Carnitine (3)  ·  Hydroxyurea (3)  ·  Valproic Acid (3)  ·  Amifampridine (2)  ·  Pyridostigmine Bromide (2)  ·  apitegromab (2)  ·  darolutamide (2)  ·  olesoxime (2)  ·  4-Aminopyridine (1)  ·  AZD5305 (1)  ·  Adrenal Cortex Hormones (1)

Sponsors

Hoffmann-La Roche (8)  ·  Biogen (4)  ·  University of Utah (4)  ·  GeneCradle Inc (3)  ·  Novartis Pharmaceuticals (3)  ·  Catalyst Pharmaceuticals, Inc. (2)  ·  Duke University (2)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (2)  ·  Scholar Rock, Inc. (2)  ·  Stanford University (2)  ·  Westat (2)  ·  AnnJi Pharmaceutical Co., Ltd. (1)  ·  AstraZeneca (1)  ·  Biocad (1)  ·  Centre Hospitalier RĂ©gional de la Citadelle (1)

Countries

United States (39)  ·  Italy (20)  ·  Germany (16)  ·  Belgium (15)  ·  Netherlands (12)  ·  Canada (11)  ·  China (11)  ·  United Kingdom (11)  ·  Poland (10)  ·  France (8)  ·  Spain (8)  ·  Australia (6)  ·  Japan (6)  ·  Brazil (5)  ·  Russia (5)

Top investigators

Dr Ching H. Wang (2)  ·  Kathryn J Swoboda, M.D. (2)  ·  Lorenzo Maggi, MD (2)  ·  Sandra P Reyna, M.D. (2)  ·  Amir Ali Hamidieh, MD (1)  ·  Anna Ferrari, MD (1)  ·  Arina V Zinkina-Orikhan, PhD (1)  ·  Bjorn Oskarsson, MD (1)  ·  Cheng-Lung Hsu, Profesor (1)  ·  Claudia A. Chiriboga, MD, MPH (1)  ·  Daniel George, MD (1)

Results publications

PMID 37148485, PMID 27939059, PMID 31420846, PMID 19846582, PMID 20808854, PMID 21216197, PMID 21754985, PMID 24300782, PMID 24876969, PMID 26444282, PMID 28460889, PMID 28688787, PMID 30061431, PMID 30337273, PMID 31434793, PMID 33501671, PMID 33626251, PMID 34089650, PMID 34320287, PMID 34942136, PMID 35110415, PMID 35241644, PMID 35763114, PMID 35906608, PMID 36244364, PMID 36288197, PMID 36632180, PMID 37409780, PMID 38330285, PMID 38705943, PMID 40458203, PMID 40802943, PMID 41224659, PMID 42031429, PMID 42385757, PMID 42546251

NIH funding

2023 (4), 2016 (3), 2017 (3), 2014 (2), N01NS42361 (2), 2005 (1), 2015 (1), 2018 (1), 2025 (1), R01HD054599 (1)